Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

Phase 2

Active, not recruiting

• Conditions: Mucopolysaccharidosis III; MPS IIIA; Sanfilippo Syndrome; Sanfilippo A
• Interventions: Biological: UX111; Drug: Prophylactic Immunomodulatory (IM) Therapy; Drug: Optimized Prophylactic IM Therapy; Drug: Adjuvant IM Therapy

• Registration Number: NCT02716246
• Lead Sponsor: Ultragenyx Pharmaceutical Inc

Brief Summary

The main objective of this study is to evaluate the efficacy and safety of UX111 for the treatment of MPS IIIA.

Detailed Description

Open-label, single dose, dose-escalation clinical trial of UX111 (scAAV9.U1a.hSGSH) injected intravenously through a peripheral limb vein. A limited course of prophylactic immunomodulatory (IM) therapy will be administered for a period of at least three months. At approved sites adjuvant IM therapy may be administered to selected participants. The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

This study was previously posted by Abeona Therapeutics, Inc and was transferred to Ultragenyx in August 2022.

Study Timeline

• Study Start: 2016-03
• Study First Submitted: 2016-03-17
• Study First Submitted QC: 2016-03-17
• Study First Posted: 2016-03-23
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-02
• Last Update Posted: 2025-01-06
• Primary Completion: 2027-07
• Study Completion: 2027-07

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Diagnosis of MPS IIIA confirmed by the following methods:

  • No detectable or significantly reduced SGSH enzyme activity by leukocyte assay, and
  • Genomic DNA analysis demonstrating homozygous or compound heterozygous mutations in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)

• Age:

  • For Cohort 1-3: From birth (participating sites in USA and Australia) OR 6 months (participating sites in Spain) to 2 years of age with no BSITD-III Cognitive Development Quotient (DQ) requirement, or older than 2 years with a BSITD-III Cognitive DQ of 60 or above (participating sites globally).
  • For Cohort 4 (participating sites in Spain): 3 months to ≤ 2 years of age with no BSITD-III Cognitive DQ requirement, or > 2 years of age with a BSITD-III Cognitive DQ of 60 or above.

• Cohort 4 only: Vaccination status based on age according to country-specific guidelines that is up to date 30 days prior to Screening as verified by documentation from the subject's primary care physician, and willing to defer vaccines through 6 months after completion of the subject's IM medication, or longer per Principal Investigator (PI) judgment. Emergency use authorization of coronavirus disease (COVID) vaccines is included unless there is an accepted medical exemption.

Read More

Exclusion Criteria

• Inability to participate in the clinical evaluation as determined by PI

• Identification of two nonsense or null variants on genetic testing of the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)

• At least one S298P mutation in the SGSH gene (based upon review of documented results from a qualified laboratory, and with confirmation with Medical Monitor)

• Has evidence of an attenuated phenotype of MPS IIIA, in the judgement of the PI

• Presence of a concomitant medical condition that precludes lumbar puncture or use of anesthetics

• Active viral infection based on clinical observations

• Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer or precludes the child from participating in the protocol assessments and follow up

• Cohorts 1-3 only: Subjects with total anti-AAV9 antibody titers ≥ 1:100 equivalent to a positive screen as determined by ELISA in serum, Cohort 4: Subjects testing positive for total anti-AAV9 antibodies as determined at Screening

• Cohorts 1-3 only: Subjects with a positive response for the enzyme-linked immunosorbent spot (ELISpot) for T-cell responses to AAV9

• Cohorts 1-3 only: Serology consistent with exposure to human immunodeficiency virus (HIV), or serology consistent with active hepatitis B or C infection, Cohort 4: Current clinically significant infections (including any requiring systemic treatment including, but not limited to, HIV; hepatitis A, B, or C; varicella zosters virus; human T-cell lymphotropic virus type 1 [HTLV-1]; tuberculosis; or COVID-19) that would interfere with participation in the study.

• Bleeding disorder or any other medical condition or circumstance in which a lumbar puncture (for collection of CSF) is contraindicated according to local institutional policy

• Visual, hearing, or other impairment sufficient to preclude cooperation with neurodevelopmental testing

• Uncontrolled seizure disorder

• Any item (braces, etc.) or circumstance which would exclude the subject from being able to undergo MRI according to local institutional policy

• Any other situation that precludes the subject from undergoing procedures required in this study

• Subjects with cardiomyopathy or significant congenital heart abnormalities

• The presence of significant non-MPS IlIA related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study

• Cohorts 1-3: Abnormal laboratory values Grade 2 or higher as defined in common terminology criteria for adverse events (CTCAE) v4.03 for gamma-glutamyl transferase (GGT), total bilirubin, creatinine, hemoglobin, white blood cell (WBC) count, platelet count, prothrombin time (PT) and activated partial thromboplastin time (aPTT), Cohort 4: Any of the following abnormal laboratory values from screening assessment:

  • Aspartate aminotransferase (AST), alanine aminotransaminase (ALT), and/or GGT and/or alkaline phosphatase ≥ 2 × upper limit of normal (ULN) and/or total bilirubin > 1.5 × ULN
  • Anemia (hemoglobin < 10 g/dL)
  • Leukopenia or leukocytosis (total WBC count < 3,000/mm3 and > 15,000/mm3 respectively)
  • Abnormal absolute neutrophil count (ANC) of < 1000/mm3
  • Platelet count < 100,000/mm3
  • Coagulopathy (international normalized ratio [INR] > 1.5) or aPTT > 40 seconds
  • Renal impairment, defined as estimated glomerular filtration rate (eGFR) below the lower limit of normal (age and sex appropriate) based on Bedside Schwartz equation

• Female of childbearing potential who is pregnant or demonstrates a positive urine or bhCG result at screening assessment (if applicable)

• Cohorts 1-3: Any vaccination with viral attenuated vaccines less than 30 days prior to the scheduled date of treatment (and use of prednisolone)

• Previous treatment by Hematopoietic Stem Cell transplantation

• Previous participation in a gene/cell therapy or enzyme replacement therapy (ERT) clinical trial

Cohort 4 only:

• Known hypersensitivity, that in the judgment of the PI, places the subject at increased risk for adverse effects.
• Willing to avoid consumption of grapefruit juice and the use of strong inhibitors of CYP3A4 and/or P-gp (eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin), strong inducers of CYP3A4 and/or P-gp (eg, rifampin, rifabutin, phenobarbital, carbamazepine, or phenytoin), or St. John's Wort 30 days prior to Screening and until completion of the sirolimus regimen, due to potential interaction with sirolimus.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 1 Low Dose	UX111	Dose of 0.5 X 10\^13 vg/kg
Cohort 2 Mid Dose	Prophylactic Immunomodulatory (IM) Therapy	Dose of 1 X 10\^13 vg/kg
Cohort 1 Low Dose	Prophylactic Immunomodulatory (IM) Therapy	Dose of 0.5 X 10\^13 vg/kg
Cohort 1 Low Dose	Adjuvant IM Therapy	Dose of 0.5 X 10\^13 vg/kg
Cohort 2 Mid Dose	UX111	Dose of 1 X 10\^13 vg/kg
Cohort 2 Mid Dose	Adjuvant IM Therapy	Dose of 1 X 10\^13 vg/kg
Cohort 3 High Dose	UX111	Dose of 3 X 10\^13 vg/kg
Cohort 3 High Dose	Prophylactic Immunomodulatory (IM) Therapy	Dose of 3 X 10\^13 vg/kg
Cohort 3 High Dose	Adjuvant IM Therapy	Dose of 3 X 10\^13 vg/kg
Cohort 4 High Dose (Spain Only)	UX111	Dose of 3 X 10\^13 vg/kg
Cohort 4 High Dose (Spain Only)	Optimized Prophylactic IM Therapy	Dose of 3 X 10\^13 vg/kg
Cohort 4 High Dose (Spain Only)	Adjuvant IM Therapy	Dose of 3 X 10\^13 vg/kg

Primary Outcome Measures

Name	Time	Method
Cerebrospinal Fluid (CSF) Heparan Sulfate (HS) (Disaccharide) Exposure	Up to Month 24 Visit	Exposure is defined as the time-normalized area under the curve (AUC) of the percentage change from baseline.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in BSITD-III Receptive Communication Raw Score Over Time	Baseline, Up to Month 24 Visit
CSF Ganglioside Type 3 (GM3) Exposure	Up to Month 24 Visit	Exposure is defined as the time-normalized area under the curve (AUC) of the percentage change from baseline.
CSF Ganglioside Type 2 (GM2) Exposure	Up to Month 24 Visit	Exposure is defined as the time-normalized area under the curve (AUC) of the percentage change from baseline.
Bayley Scales of Infant and Toddler Development-Third Edition (BSITD-III) Cognitive Raw Scores Over Time	Up to Month 24 Visit
Percent Change from Baseline in CSF HS	Baseline, Up to Month 24 Visit
Change From Baseline in BSITD-III Expressive Communication Raw Score Over Time	Baseline, Up to Month 24 Visit
Percent Change From Baseline in Total Cortical Volume	Baseline, Up to Month 24 Visit

Trial Locations

Locations (5)

Vall d'Hebron Barcelona Hospital Campus; 🇪🇸 Barcelona, Spain

Women's and Children's Hospital; 🇦🇺 North Adelaide, South Australia, Australia

Children's Hospital of Pittsburgh; 🇺🇸 Pittsburgh, Pennsylvania, United States

Hospital Clínico Universitario de Santiago; 🇪🇸 Santiago De Compostela, Spain

Nationwide Children's Hospital; 🇺🇸 Columbus, Ohio, United States